---
title: "Entrada Therapeutics, Inc. (TRDA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TRDA.US.md"
symbol: "TRDA.US"
name: "Entrada Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T22:35:53.725Z"
locales:
  - [en](https://longbridge.com/en/quote/TRDA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TRDA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TRDA.US.md)
---

# Entrada Therapeutics, Inc. (TRDA.US)

## Company Overview

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.entradatx.com](https://www.entradatx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 257 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -96.67% |  |
| Net Profit YoY | -770.34% |  |
| P/B Ratio | 0.80 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 216306368.45 |  |
| Revenue | 5738000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -48.28% | E |
| Profit Margin | -2895.05% | E |
| Gross Margin | -3677.60% | E |
| Revenue YoY | -96.67% | E |
| Net Profit YoY | -770.34% | E |
| Total Assets YoY | -31.03% | E |
| Net Assets YoY | -35.09% | E |
| Cash Flow Margin | 79.28% | C |
| OCF YoY | -96.67% | E |
| Turnover | 0.01 | E |
| Gearing Ratio | 19.27% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Entrada Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-96.67%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-770.34%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.80",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "216306368.45",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5738000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-48.28%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-2895.05%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-3677.60%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-96.67%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-770.34%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-31.03%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-35.09%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "79.28%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-96.67%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "19.27%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.30 | 200/386 | 11.05 | 10.12 | 9.08 |
| PB | 0.80 | 73/386 | 1.32 | 0.90 | 0.55 |
| PS (TTM) | 37.70 | 224/386 | 17.82 | 5.12 | 1.69 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 78% |
| Hold | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.04 |
| Highest Target | 25.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TRDA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TRDA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TRDA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TRDA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**